Introduction: The aim of this study was to examine the association between plasma
| INTRODUC TI ON
Parturition is preceded by complex maternal-fetal interactions that are still not fully understood despite several decades of intense research involving in vitro as well as in vivo studies of both humans and animals. 1 It is now well established that hormones such as progesterone, estrogen, cortisol, corticotropin-releasing hormone, and oxytocin play a critical role in maintaining uterine quiescence throughout gestation and in triggering the cascade of events that lead to labor and cervical ripening.
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In 1974 Csapo et al 3 found lower serum progesterone concentrations in 11 women with preterm labor than in 12 women with term labor. Whereas some later studies have also found lower plasma progesterone concentrations in the third trimester in preterm vs term labor in women with a previous preterm birth, 4 others have found no difference in maternal progesterone concentrations in either serum or amniotic fluid. [4] [5] [6] [7] [8] [9] [10] [11] [12] Recent studies have found low saliva progesterone concentrations in women with preterm labor 13 and preterm delivery. 14 A more consistent finding has been lower progesterone :
estradiol ratios in women in labor compared with women not in labor both preterm and term. 3, 6, 9, 11 Progesterone, estradiol, and estriol in relation to preterm delivery have mainly been investigated in singleton pregnancies 3, 4, 6, 7, [9] [10] [11] [12] [13] [14] and few results have been published from multiple pregnancies. 12, 15, 16 Several studies have now shown that progesterone treatment during the second and third trimester of pregnancy reduces the risk of preterm delivery in women with a singleton pregnancy and a short cervical length or a history of a previous preterm delivery. 17, 18 No effect of progesterone treatment has been found in cohorts of unselected women pregnant with twins, whereas women with a twin pregnancy and a short cervical length may benefit from progesterone treatment to prevent preterm delivery. 19, 20 Few studies have measured hormone concentrations in women treated with prophylactic progesterone during the second trimester. 15, 21, 22 The purpose of this study was to examine the association between second and third trimester concentrations of progesterone, estradiol, and unconjugated estriol with cervical length and preterm delivery in asymptomatic twin pregnancies. Second, we wished to examine the effect of prophylactic vaginal progesterone treatment on plasma hormone concentrations.
| MATERIAL AND ME THODS
This is a sub-study of the Prevention of Preterm Delivery in Twins study, a double-blinded, placebo-controlled randomized clinical trial examining the effect of vaginal micronized progesterone on the prevention of preterm delivery in diamniotic twin pregnancies.
In this study a total of 677 women were randomized to treatment women; 334 from the progesterone group and 341 from the placebo group. We used an interactive voice-response randomization system to randomize the women in a 1:1 ratio of progesterone to placebo treatment. The project medicine was packed in sealed boxes containing pessaries that were identical in appearance for the active treatment and the placebo treatment. Participants and study personnel were blinded for the treatment assignment for the whole duration of the trial, and the code was not broken until all children were at least 18-months old due to a planned long-term follow up of the twins. Further details of the randomized clinical trial, such as the inclusion criteria, randomization, study treatment, and definition of primary and secondary outcomes have been described elsewhere.
23
Of the 17 participating departments in the Prevention of Preterm Delivery in Twins study, five collected blood samples from 191 women for this sub-study. All women signed an informed consent form. The first blood sample (baseline) was collected at their inclusion in the study at 18-24 weeks of gestation, before treatment with progesterone or placebo pessaries started.
Approximately 80% had a cervical length measurement. The measurement was performed at their inclusion, at the same time as the first blood sample was collected and before progesterone or pla- 
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been described elsewhere. 24 We aimed to collect the second blood sample after 4-8 weeks of treatment at 22-32 weeks of gestation.
For this sub-study we excluded one second blood sample because it had been collected at 35 weeks of gestation. Figure 1 shows the flowchart for the study population.
| Analysis of samples
Venous blood was collected in heparinized tubes and plasma was separated within 30 minutes after the blood was collected and stored at −20°C until analyzed. All samples were analyzed during the same period of time. They were analyzed for progesterone, estradiol, and unconjugated estriol using the Beckman Access Assay (Beckman Coulter Inc, CA, USA), a competitive immunoassay using direct chemiluminescent technology. For the progesterone assay, sensitivity was 0.25 nmol/L, intra-assay CV 8.2%, and inter-assay CV 7.9%, respectively. For the estradiol assay, sensitivity was 73 pmol/L and intra-assay CV 15.3%. For the unconjugated estriol assay, sensitivity was 0.059 pmol/L and intra-assay CV 3.5%.
| Statistical analyses
We used Stata version 12.0 (StataCorp, TX, USA). Hormone concentrations and ratios between the hormone concentrations were summarized by median and interquartile range and comparisons between the groups were performed using the Mann-Whitney U test. The P trend across more than two groups was evaluated using
Cuzick's extension of the Wilcoxon rank-sum test. Figure 2 shows a diagram of the study analyses.
The trajectory of the hormone concentrations and ratios between hormone concentrations during pregnancy was described by plotting the hormone measurements from both the first and second blood sample according to gestational age at the time of collecting the blood sample. For these analyses we included only the women treated with the placebo. This was done to exclude bias from a potential effect of the progesterone treatment on hormone concentrations in the progesterone group. The associations with gestational age at the time of collecting the blood samples were reported as the percentage change per week and were assessed by a linear regression analysis of log-transformed hormone concentrations.
We investigated the relation between cervical length and hormone concentrations in the first blood sample and used Spearman's rho to assess the correlations. In addition, we compared the hormone concentrations in women with a cervical length below and at or above 30 mm, which was the cut-off used for cervical length in the initial report from the Prevention of Preterm Delivery in Twins study. 24 We included the women treated for progesterone and placebo for these analyses, as the cervical length was measured and the first blood sample collected when they were included in the study, before initiating progesterone or placebo treatment.
F I G U R E 1 Flowchart for the study population. PREDICT, Prevention of Preterm Delivery in Twins study; GA, gestational age
For the assessment of hormone concentrations in relation to preterm delivery, we included only women from the placebo group. In these analyses, we thus excluded women from the progesterone group to prevent any interference on the outcome of preterm delivery from progesterone treatment. All women were categorized according to gestational age at delivery into three groups: term delivery (37 weeks of gestation or greater), late preterm delivery (34 + 0 to 36 + 6 weeks of gestation), and early preterm delivery (less than 34 weeks of gestation). We adjusted for gestational age at the time of collecting the blood sample using a linear regression analysis of the log-transformed hormone concentrations, and mixed-effects models adjusted for repeated measurements were applied to assess whether the variations in hormone concentrations differed in the sample number (ie at baseline vs after 4-8 weeks of treatment) for the three groups.
Finally, we compared the median hormone concentrations as well as the median weekly change in hormone concentration between the first and second blood sample in the progesterone and placebo group. We adjusted for gestational age at time of collecting the blood sample using a linear regression analysis of the logtransformed hormone concentrations. We used a mixed-effects models adjusted for repeated measurements to assess whether the variations in hormone concentrations differed in the sample number (ie at baseline vs after 4-8 weeks of treatment) in the two treatment groups.
| Ethical approval
The trial was registered on EudraCT (2006-000503-41) and in
ClinicalTrials.gov (NCT00329914). The Danish Data Protection
Agency, the Danish and Austrian Medicines Agencies, the Danish Scientific Ethical Committee, and the Ethical Committee of the Medical University of Vienna approved the study.
| RE SULTS
The 191 women who were included in this sub-study were more likely to carry monochorionic twins and they had a lower body mass index than the women whose blood samples were not available for analysis (Table S1 ). The two groups of women were comparable with respect to the main outcome of the Prevention of Preterm Delivery in Twins study, ie, delivery before 34 weeks' gestation.
Among the women in this sub-study, a total of 96 were allocated to receive placebo treatment and 95 to receive progesterone treatment. The first blood sample (baseline) was collected at 18 + 3 to 24 + 6 weeks of gestation (median gestational age 21 + 5 weeks) and the second at 22 + 6 to 32 + 6 weeks of gestation (median 26 + 5 weeks), ie, there was some overlap between the time intervals for the two sets of samples. Women who had only the baseline blood sample were more likely to be smokers at inclusion and to deliver before 34 weeks (Table S2 ). The estradiol : estriol ratio did not change with increasing gestational age (−0.7% (95% CI; −2.6-1.1, r 2 =0.004).
A total of 155 (81.2%) women had a cervical length measurement before the start of progesterone or placebo treatment.
Among these, 12 (7.7%) had a cervical length less than 30 mm. We next examined the association between hormone concentrations and preterm delivery before 34 weeks in the women treated with a placebo (Table 1 ). There was a statistically significant trend toward higher progesterone and estradiol concentrations at baseline before treatment; across the three groups, P was 0.04 for progesterone and 0.02 for estradiol. These associations were not observed in the second sample. There was no association between the observed weekly change in hormone concentration between samples and preterm delivery. The results were similar in analyses adjusting for gestational age at the time of collecting the blood sample (Table S3) , and the hormone concentrations did not vary with sample number (ie at baseline vs after 4-8 weeks)
for the three groups (P = 0.09 for progesterone, P = 0.05 for estradiol, and P = 0.28 for unconjugated estriol) after adjustment for gestational age at the time of collecting the blood sample.
F I G U R E 4
Cervical length in relation to hormone concentrations at the time of inclusion into the study (n = 155 women). Women from both the progesterone group (n = 81) and the placebo group (n = 74) were included since blood samples and their cervical length measured before treatment started [Color figure can be viewed at wileyonlinelibrary.com] We did not observe an association between hormone concentration ratios and gestational age at delivery (Table S4) . The results were similar after adjusting for gestational age at the time of collecting the blood sample (data not shown). Table 2 shows the measured hormone concentrations in the women treated with progesterone and placebo. The hormone concentrations were comparable for the two groups at baseline before treatment with progesterone or placebo and after 4-8 weeks of treatment. Figure S2 shows the measured progesterone concentration in the two blood samples for each participant according to gestational age at the time of collecting the blood sample. The second blood sample was collected after 30 weeks' gestation in some of the women treated with progesterone but in none of the women treated with the placebo. Analyses adjusting for gestational age at the time of collecting the blood sample confirmed that progesterone treatment was not associated with different hormone concentrations (Table S5 ). The observed weekly change in progesterone concentration between samples was higher in the women treated with progesterone, (median 47 nmol/L interquartile range 31-66) than in the women treated with placebo (36 nmol/L interquartile range 23-56); P = 0.02 (Table 2 ). However, after adjustment for gestational age at the time of collecting the blood sample, hormone concentrations were not found to vary differently (ie, at baseline vs after 4-8 weeks of treatment) for the two groups (P = 0.09 for progesterone, P = 0.50 for estradiol, and P = 0.57 for unconjugated estriol).
TA B L E 1 Hormone concentrations according to gestational age (GA) at delivery in 96 women treated with placebo
The progesterone : estriol ratio in the second sample was higher in the progesterone group than in the placebo group (P = 0.03, Table   S6 ), whereas all other ratios between hormone concentrations were comparable for the two treatments. These results were similar after adjustment for gestational age at the time of collecting the blood sample.
| D ISCUSS I ON
In this study we investigated the association between cervical length and preterm delivery and peripheral plasma progesterone, estradiol, and unconjugated estriol concentrations in women with a twin pregnancy. We did not find an association between plasma hormone concentrations and cervical length, either as a continuous measurement or using a cut-off point of 30 mm at 18-24 weeks of gestation. Recently, Priya et al 14 found a positive association between salivary progesterone concentration and cervical length in singleton gestations but to our knowledge the association has not previously been examined in twin gestations. This is interesting, because vaginal progesterone treatment has been shown to reduce the risk of preterm delivery in women with a singleton pregnancy and a short cervical length at mid-gestation 18 but not in unselected singleton gestations. 17 Whereas it is well established that there is no benefit of progesterone treatment in unselected twin gestations,
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there may be an effect in twin gestations with a short cervix. 19 We did not find evidence of an increased plasma hormone concentration and gestational age at delivery. This could be explained by the fact that these hormones are a measure of the placental mass. 26 If the placenta follows a developmental program just as the fetus does, the further along the developmental pathway the placenta is, the more likely the placenta is to trigger birth. 1 It is, however, important to note that the association was not present in the second sample in our study, and a recent study of serial hormone measurements in twin gestations suggests that progesterone, estradiol, and estriol are not robust biomarkers of preterm delivery. 16 Furthermore, in humans, unlike most other animal species, the inhibitory influence of progesterone on the uterus diminishes before parturition and a low concentration of progesterone does not seem to be critical for the onset of labor. 2 The effect of progesterone is modified by other factors such as levels of the progesterone receptors and the withdrawal of progesterone action is believed to be functional.
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Findings from singleton pregnancies indicate that the progesterone : estradiol ratios are lower in women in labor than in women not in labor, as well as in women delivering preterm. 3, 6, 9, 11 This was not the case in our study of twin pregnancies, and no other trends in ratios were observed.
The strength of our study was the population of 191 women with available blood samples, of whom 80% had a cervical length measurement at their inclusion in the study, and 167 women had a second blood sample collected after 4-8 weeks. In addition, the women were randomized to either progesterone or placebo treatment, which enabled us to investigate the effect of progesterone treatment on hormone concentrations in vivo. We excluded women who did not start taking the project treatment (n = 2), and overall compliance in the Prevention of Preterm Delivery in Twins study was high (> 80%). 23 However, there are also some weaknesses in our study. The mean body mass index was lower among women who were included in this sub-study compared with the women who were excluded. This could have affected our results, although the proportion who delivered preterm was comparable between included and excluded women. Samples were collected from peripheral venous blood, and as mentioned, hormone concentrations in these samples may not fully reflect the processes that occur in the cervix and uterus. A potential limitation to our study is that hormonal changes occurring closer to delivery would not have been detected by our sampling protocol. In addition, the fact that not all women had two blood samples collected may have affected our results on the effect of progesterone treatment on measured hormone concentrations. However, although the proportion of women who delivered preterm was higher among women who did not have the second blood sample collected, these women were not more likely to have received placebo treatment.
| CON CLUS ION
Second and early third trimester progesterone, estradiol, and unconjugated estriol concentrations are associated with neither cervical length nor preterm delivery in women with twin pregnancies.
Vaginal progesterone administration did not increase progesterone concentration and did not affect estradiol or unconjugated estriol concentrations in our study. Any beneficial effects of vaginal progesterone on preterm delivery in the setting of a short cervix are likely to be due to direct local actions of the progesterone released.
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